Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Castle Biosciences, Inc.NASDAQ: CSTL

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 28.9% from a year ago

Cash & equivalents stood at $63.76M at the end of Q1 FY2026, down 28.9% from a year earlier and down 45.4% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Cash & equivalents amounted to 11.6% of total assets at the end of Q1 FY2026, down 6.2 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -28.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$63.76M-45.4% QoQ
Last fiscal yearDec 2025
$116.73M-2.5% YoY
Year agoMar 2025
$89.69M-28.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.9%——
1 year-2.5%——
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
116.73M USD
Year-over-year change
-2.5%
4-year CAGR
-22.9%

Cash & Equivalents vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's Mar 2026 cash & equivalents of $63.76M is the 6th highest of the 8 companies compared; the peer median is $124.4M.
  • Its year-over-year change of -28.9% is the 7th highest of 8, against a peer median of +35.5%.
  • Cash & equivalents amounts to 11.6% of total assets for CSTL, versus a peer median of 20.2%.
CSTL Competitors Peer median
Cash & Equivalents for CSTL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GHGuardant Health, Inc.Sep 2026$1.03B +77.0%+38.7%54.5%
VCYTVeracyte, Inc.Jun 2026$299.52M +36.5%+33.0%20.2%
NEONeoGenomics, Inc.Jun 2026$145.54M -5.9%-15.4%10.8%
MYGNMyriad Genetics, Inc.Mar 2026$124.4M +35.5%+38.0%18.5%
PSNLPersonalis, Inc.Mar 2026$73.59M +3.7%+11.7%22.6%
CSTLCastle Biosciences, Inc.Mar 2026$63.76M -28.9%-1.7%11.6%
BDSXBiodesix, Inc.Mar 2026$25.57M +45.3%-23.9%27.0%
MDXHMDxHealth S.A.Jun 2026$19.21M -41.5%+23.3%14.5%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding CSTL) $124.4M+35.5%+23.3%20.2%

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents329.63M122.95M98.84M119.71M116.73M
Short-term Investments0135.68M144.26M173.42M182.78M
Net Receivables17.28M23.48M38.3M51.22M43.38M
Inventory2.02M3.98M7.94M8.14M10.25M
Other Current Assets4.81M6.21M6.29M7.67M7.96M
Total Current Assets353.74M292.29M295.64M360.15M361.1M
Property, Plant & Equipment (Net)16.88M26.5M37.74M62.71M112.24M
Goodwill010.69M10.69M10.69M10.69M
Intangible Assets88.92M115.66M106.64M95.54M88.88M
Long-term Investments1.31M0000
Tax Assets00000
Other Non-current Assets1.72M2.2M2.63M2.15M5.65M
Total Non-current Assets108.83M155.04M157.71M171.08M217.46M
Total Assets462.57M447.33M453.34M531.24M578.56M
Account Payables2.55M4.73M10.27M6.9M18.71M
Short-term Debt000278K417K
Tax Payables695K37K01.08M0
Deferred Revenue00000
Other Current Liabilities16.91M25.67M30.69M774K42.34M
Total Current Liabilities24.89M36.13M47.67M49.39M68.68M
Long-term Debt0009.75M9.64M
Deferred Tax Liabilities635K428K206K1.61M2.34M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities18.29M0001.5M
Total Non-current Liabilities25.95M12.05M14.4M26.01M39.01M
Total Liabilities50.83M48.18M62.07M75.4M107.68M
Common Stock25K27K27K28K30K
Retained Earnings(93.77M)(160.91M)(218.37M)(200.13M)(224.28M)
Accumulated OCI0(381K)136K230K267K
Other Stockholders Equity00000
Minority Interest00000
Total Equity411.74M399.15M391.27M455.84M470.87M
Total Debt8.2M13.4M15.34M26.34M36.91M
Net Debt(321.43M)(109.55M)(83.51M)(93.37M)(79.82M)

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.